1218-35-5
1218-35-5
Chemical Structure
Xylometazoline hydrochloride
- CAS 番号: 1218-35-5
- Formula:C16H25ClN2
- Molecular Weight:280.84
IUPAC Name: 2-(4-(tert-butyl)-2,6-dimethylbenzyl)-4,5-dihydro-1H-imidazole hydrochloride
InChIKey: YGWFCQYETHJKNX-UHFFFAOYSA-N
SMILES: CC1=C(CC2=NCCN2)C(C)=CC(C(C)(C)C)=C1.Cl
Biological Activity: Xylometazoline hydrochloride is an α-adrenergic receptor agonist (Ki=0.05-1.7 μM). Xylometazoline hydrochloride can constrict nasal blood vessels and increase nasal airflow. Xylometazoline hydrochloride can be used in nose stuffiness and runny nose research[1][2][3][4].
| 製品番号 | 製品名 | 純度 | 製品説明 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Xylometazoline hydrochloride | 99.94% | Xylometazoline hydrochloride is an α-adrenergic receptor agonist (Ki=0.05-1.7 μM). Xylometazoline hydrochloride can constrict nasal blood vessels and increase nasal airflow. Xylometazoline hydrochloride can be used in nose stuffiness and runny nose research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Xylometazoline hydrochloride (Standard) | ≥98% | Xylometazoline (hydrochloride) (Standard) is the analytical standard of Xylometazoline (hydrochloride). This product is intended for research and analytical applications. Xylometazoline hydrochloride is an α-adrenergic receptor agonist (Ki=0.05-1.7 μM). Xylometazoline hydrochloride can constrict nasal blood vessels and increase nasal airflow. Xylometazoline hydrochloride can be used in nose stuffiness and runny nose research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Xylometazoline-d4 hydrochloride | Xylometazoline-d4 hydrochloride is deuterated labeled Xylometazoline hydrochloride (HY-B0475). Xylometazoline hydrochloride is an α-adrenergic receptor agonist (Ki=0.05-1.7 μM). Xylometazoline hydrochloride can constrict nasal blood vessels and increase nasal airflow. Xylometazoline hydrochloride can be used in nose stuffiness and runny nose research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Ronald Eccles, et al. The nasal decongestant effect of xylometazoline in the common cold. Am J Rhinol. 2008 Sep-Oct;22(5):491-6. [Content Brief]
- [2]. Britta Haenisch, et al. Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. [Content Brief]
- [3]. M Kar, et al. Development of an intranasal formulation containing indomethacin and xylometazoline for rhinosinusitis treatment. Eur Rev Med Pharmacol Sci. 2022 Dec;26(2 Suppl):65-71. [Content Brief]
- [4]. Ayse Ipek Akyuz Unsal, et al. Ophthalmic adverse effects of nasal decongestants on an experimental rat model. Arq Bras Oftalmol. 2018 Jan-Feb;81(1):53-58. [Content Brief]
